The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy

Platinum-based drugs are widely used in clinical practice. Their efficacy varies widely among patients, which may be due to a disruption of the expression of ERCC1 - excision repair protein. In the prospective study a strictly quantitative analysis of the ERCC1 protein expression was carried out in...

Full description

Saved in:
Bibliographic Details
Main Authors: T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/65
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platinum-based drugs are widely used in clinical practice. Their efficacy varies widely among patients, which may be due to a disruption of the expression of ERCC1 - excision repair protein. In the prospective study a strictly quantitative analysis of the ERCC1 protein expression was carried out in surgical biopsy specimens of serous ovarian cancer by flow cytometry. ERCC1 expression was revealed in 100% of cases, but the expression level of the marker (the percentage of cells expressing ERCC1) varied significantly between tumors: the minimum was 40%, the maximum - 77%, the median - 64.5%; the average - 64.3+9.0%. The analysis of the Kaplan-Mayer curves showed an inverse relationship between the expression of ERCC1 and the duration of the relapse-free period during a 40-month follow-up after the first-line platinum-taxane chemotherapy (p
ISSN:0235-2990